For the Quarter Ending September 2025
North America
• In United States, the Methyldopa Price Index rose quarter-over-quarter in Q3 2025, driven by increasing production costs.
• Methyldopa production costs increased, influenced by a 2.6% rise in August 2025 Producer Price Index.
• The Methyldopa demand outlook remained stable, supported by strengthening US pharmaceutical market sentiment in Q3 2025.
• Retail sales increased 5.42% in September 2025, and unemployment was 4.3%, bolstering overall healthcare spending.
• Energy costs for chemical manufacturing, including natural gas and electricity, climbed in September 2025.
• US manufacturing inventories tightened in Q3 2025, while overall chemical industry activity contracted.
• Consumer confidence declined to 94.2 in September 2025, and industrial production grew only 0.1% year-over-year.
• The Methyldopa Price Index is forecast to remain firm due to persistent cost pressures and steady demand.
Why did the price of Methyldopa change in September 2025 in North America?
• Rising energy costs and a 2.6% Producer Price Index increase in August 2025 elevated production expenses.
• Strengthening US pharmaceutical market sentiment and surging drug approvals supported stable Methyldopa demand.
• Tightening US manufacturing inventories and a 3.0% CPI in September 2025 contributed to upward price pressure.
APAC
• In China, Methyldopa Price Index fell in Q3 2025, influenced by deflationary CPI of -0.3% in September 2025.
• Methyldopa production costs experienced downward pressure in Q3 2025 due to declining PPI of -2.3% in September 2025.
• Demand for Methyldopa was supported by a surge in China's pharmaceutical sector demand during Q3 2025.
• Industrial production in China rose 6.5% year-on-year in September 2025, supporting stable Methyldopa demand.
• Retail sales grew 3.0% year-on-year in September 2025, with stable 5.2% unemployment, supporting healthcare spending.
• Ethylene and Benzene feedstock costs dipped in Q3 2025, contributing to lower Methyldopa production expenses.
• Ample chemical inventories and significant overcapacity in Q3 2025 contributed to a bearish Methyldopa price outlook.
• A contracting Manufacturing Index in September 2025 and pessimistic consumer confidence (89.6) affected overall market sentiment.
Why did the price of Methyldopa change in September 2025 in APAC?
• Deflationary pressures, with CPI falling 0.3% in September 2025, lowered overall pricing environment.
• Producer Price Index declined 2.3% in September 2025, reducing input costs and overall pricing power.
• Ample chemical inventories and overcapacity in Q3 2025 contributed to a bearish Methyldopa price.
Europe
• In Germany, the Methyldopa Price Index fell quarter-over-quarter in Q3 2025, driven by declining feedstock costs.
• Methyldopa production costs declined in Q3 2025, influenced by a -1.7% Producer Price Index in September 2025.
• Demand for Methyldopa remained stable in Q3 2025, supported by an expanding German pharmaceutical market.
• European phenol markets experienced downward pricing pressure during Q3 2025, impacting Methyldopa input costs.
• Benzene feedstock costs sharply declined in Europe in August 2025, contributing to lower Methyldopa production expenses.
• High energy costs continued to impact chemical manufacturing in Europe during Q3 2025, despite other cost reductions.
• Germany's Manufacturing Index contracted in September 2025, signaling a slowdown in overall industrial output.
• Industrial production in Germany declined by 1.0% year-on-year in September 2025, affecting raw material availability.
• Phenol inventory levels swelled in Germany during Q3 2025, creating an oversupply in the regional market.
Why did the price of Methyldopa change in September 2025 in Europe?
• Producer Price Index declined by 1.7% in September 2025, reducing Methyldopa production costs.
• Benzene feedstock costs sharply declined in August 2025, lowering Methyldopa manufacturing expenses.
• Phenol inventory oversupply in Q3 2025 exerted downward pressure on Methyldopa intermediate pricing.
For the Quarter Ending December 2022
North America
Over the first half of the fourth quarter, Methyldopa price gradually increased at a moderate rate in North America. End-user demand from the pharmaceutical industry kept Methyldopa costs on the sturdy end. Additionally, there was a steep decline in supply chain disruption in the six months leading up to November across several measures, including shipping costs, which further strengthened the Methyldopa market in an upward direction.
Prices for Methyldopa stayed on the North side till November when they were recorded at USD 159500 /MT CFR Los Angeles. However, towards the end of q4, they started to fall precipitously due to a major decrease in their offtakes.
APAC
In the fourth quarter of 2022, Methyldopa prices in the Asia Pacific area, particularly in China, sharply declined. However, prices remained on the upper side throughout the initial half of q4 due to increased downstream demand balanced with supplies among market participants. On the other hand, the ease in supply chain disruption in November compared to October, including the lower shipping costs, encouraged the traders and suppliers to raise their orders. With the year 2022 concluding, China's production activities started to decline, particularly after November, due to an increase in COVID-19 instances and a reduction in freight costs, supporting the price trend of Methyldopa in China. Overall, the Methyldopa costs noted in the middle of the fourth were assembled at USD 150655/MT FOB Shanghai in China.
Europe
The Methyldopa market in Europe followed a similar trajectory to that in Asia Pacific in the fourth quarter of 2022. Due to a rise in demand from the end-user pharmaceutical business, the market trend started off well up until November and reached an assembly price of USD 161850/MT CFR Hamburg in Germany. After December, Methyldopa pricing inquiries from the downstream industry started to decline dramatically, which reinforced the drug's weaker price trend because market participants had plenty of supply and little to no demand. Also, fresher quotations declined in December because of suppliers' high stock levels brought on by the market closure.
For the Quarter Ending September 2022
North America
In the North American region, Methyldopa prices witnessed a stable market sentiment during the third quarter of 2022 due to consistent demand balanced with the supply side from the downstream pharmaceutical sector. Additionally, adequate inventories in the domestic market have noticeably propelled Methyldopa market sentiments to be on the firm side. Also, the zero covid policy in China has abrupted the global supply chain and somewhat supported the price trends of Methyldopa in the United States. Furthermore, towards the termination of Q3, the prices witnessed for Methyldopa went down steadily and were settled at USD 158000/ MT CFR Los Angeles.
Asia Pacific
During the third quarter of 2022, the pricing trend for Methyldopa in the Asia Pacific showed a stable tendency. Consistent COVID-19 cases and strict lockdown conditions in China during H1 of Q3 kept the market of Methyldopa on the weaker side. Further, weak global demand with soaring energy prices dulled overall trading momentum, affecting the price trends of Methyldopa. Also, owing to fewer purchasing activities, domestic merchants were left with stockpiled products, which compelled them to reduce the prices and destock their lists. With the ending of Q3 2022, the price of Methyldopa witnessed a decremented trend with the settlement of USD 149200/MT FOB Shanghai in China.
Europe
In the European region, the prices of Methyldopa witnessed a negative market sentiment backed by the weaker downstream demand and trading activities from the exporting countries. The war between Russia and Ukraine has affected the trading propensity throughout the region, resulting in slowed commodity flow, negatively impacting the price trend for Methyldopa in Europe. Additionally, the providers had sufficient stocks to meet the overall domestic demand. Also, with the ending of Q3, the market witnessed a decremented trend owing to lessening need and halted supplies from the APAC region. The prices recorded at the end of Q3 were settled at USD 160750MT CFR Hamburg.
For the Quarter Ending June 2022
North America
The North American region witnessed a mixed sentiments in its pricing trend of Methyldopa during the second Quarter of 2022, backed by fluctuation in buying and purchasing activities in the regional market and in downstream demand from end-user enterprises, mainly from the pharmaceutical sector. Moreover, the variable upstream Raw material prices in the second quarter kept the Prixes of Methyldopa affected. Also, the extended port congestion leading to higher freight charges and shortage of cargoes resulted in the price enhancement of Methyldopa API during the end of Q2. Besides, the heightened demand and rerouting in trading activities owing to geopolitical and logistic tension affected the market sentiments. Altogether the prices recorded for Methyldopa were assessed at USD 157150/MT CFR Los Angeles.
Asia Pacific
During the Second Quarter of 2022, the prices of Methyldopa showcased steady trends in its prices in the APAC region backed by consistent demand in the regional market. Further, rising upstream feed Veratraldehyde prices result in the stably price enhancement of Methyldopa in the market. constant downstream demand resurgence of covid cases and the extended trade disruption witnessed a positive sentiment of Methyldopa in the domestic market. Besides that, toward the end of Q2, the prices for Methyldopa went steady owing to its slight decrease in continual demand. Hence, the market surged in the second quarter with a settlement of USD 149000/MT FOB Shanghai.
Europe
The Prices of Methyldopa mimics similar pricing sentiment in the European market as per North America during the Second Quarter of 2022, backed by varying upstream feed Vertraldehyde cost and its unavailability. Furthermore, the steady downstream demand with sufficient stock with the suppliers, kept the prices of Methyldopa stable in the market. Also, an increase in energy and crude oil prices amid Russian-ukraine Geopolitical tension was one factor that resulted in higher Methydopa Cost in the region during themed of Q2. Additionally, the cost of shipping containers and scheduled delays between the APAC-European region also exacerbated Methyldopa prices efficiently in the European region. Towards the termination of q2 the prices went down and were recorded as UASD 165510/MT CFR Hamburg.
